VIRAL SAFETY & VIROLOGY
Laboratory Services Ready for Clinical Research

Introduction and Scope

In clinical research, virology and viral safety represent a safety-critical testing domain with high relevance for patient safety, product safety, and regulatory compliance. Particularly in cell and gene therapies, vaccine studies, immunosuppressed populations, and protocols requiring long-term follow-up, monitoring of viral load, viral shedding, and replication-competent virus risks is critical not only for scientific validity but also for audit readiness.

The HelixLab Viral Safety & Virology infrastructure, positioned within the Omega CRO ecosystem, is structured in line with protocol-compliant sample management, standardized analytical workflows, data integrity (ALCOA+), and traceability (chain-of-custody) principles. The scope is modularly designed to address both virological testing in clinical samples and viral safety testing specific to cell and gene therapy programs (e.g., RCL/RCR).

Pre-Analytical Processes

In virological testing, result reliability depends on strict pre-analytical standardization. Accordingly, the study-specific pre-analytical package covers visit window management (sampling time, transfer duration, stability), sample identity verification with proper patient–sample linkage and timestamping, defined transport conditions (temperature, packaging, courier planning), full chain-of-custody traceability from collection to laboratory receipt, and clear non-conformance workflows for issues such as hemolysis, clotting, insufficient volume, labeling errors, and temperature excursions.

Analytical Processes

The analytical phase is performed using validated methods and Standard Operating Procedures (SOPs), with qPCR workflows designed to ensure contamination prevention and full traceability during extraction and amplification. Standard controls include the use of positive and negative controls alongside appropriate internal controls, lot-change management with performance verification, ongoing instrument and batch consistency monitoring through Quality Control (QC) trending, and a structured second-review and approval process for results.

Post-Analytical Processes and Reporting

Test results are reported in protocol-defined formats and frequencies, with critical findings (such as viral load exceeding safety thresholds) managed through specific notification workflows. Data transfer is aligned with sponsor Electronic Data Capture (EDC) and electronic Case Report Form (eCRF) systems, and outputs may include viral load reports with method details, viral shedding time-series data, RCL/RCR results, sample suitability and deviation summaries, as well as interim data packages and data dictionaries.

partner infrastructures

Laboratory, analytical, and operational services provided within the Omega ecosystem are delivered through Omega’s internal units or authorized partner infrastructures that comply with applicable standards, depending on the nature of the study, regulatory requirements, and methodological scope. Accreditations, certifications, and official authorizations apply at the level of the unit or partner organization where the service is actually performed and are assessed on a study-specific basis for each service category.

Viral Safety & Virology Services Offered

Viral load analyses are performed using quantitative Polymerase Chain Reaction (qPCR)-based approaches. Depending on the protocol, qualitative or quantitative reporting is provided for appropriate sample matrices, including serum, plasma, whole blood, Peripheral Blood Mononuclear Cells (PBMC), urine, Bronchoalveolar Lavage (BAL), and cerebrospinal fluid (CSF).

Viruses tested (configured based on study requirements):

  • Adenovirus (ADV)
  • Cytomegalovirus (CMV)
  • Epstein–Barr Virus (EBV)
  • Hepatitis B Virus (HBV)
  • Hepatitis C Virus (HCV) – qualitative/quantitative
  • Human Herpesvirus-6 (HHV-6)
  • Influenza A
  • Metapneumovirus (MPV)
  • BK Polyomavirus (BKV)
  • JC Polyomavirus (JCV)
  • Respiratory Syncytial Virus (RSV)
  • Parainfluenza virus types 1–4
  • SARS-CoV-2 (qualitative/quantitative)

Viral shedding assessments may be critical for infectivity and environmental risk management, particularly in vaccine, oncology, immunology, and cell/gene therapy studies. Sample types (e.g., swabs, stool, urine, serum/plasma) and visit windows are defined per protocol, with sample stability and transport conditions planned on a study-specific basis.

In Cell and Gene Therapy (CGT) programs, viral safety testing performed on viral vectors, manufacturing processes, and patient samples is decisive for product release decisions and safety monitoring. Based on study requirements, HelixLab activates the following test blocks modularly:

  • Replication-Competent Lentivirus (RCL) testing
  • Replication-Competent Retrovirus (RCR) testing
  • Viral infectivity assessments (study-design dependent)
  • Vector- or virus-specific qPCR-based monitoring panels (study-specific)

Sample types used in virology and viral safety testing are determined based on protocol, indication, and risk assessment. Common specimen types include serum, plasma, whole blood, PBMC, urine, stool, CSF, BAL, and nasal/oropharyngeal swabs. For each specimen type, pre-analytical requirements (tube type, volume, anticoagulant, stability, maximum transfer time) are defined at study initiation and reflected in site instructions.

Regulatory and Quality Compliance Framework

Viral safety and virology operations are conducted in compliance with ICH GCP (Good Clinical Practice), GCLP (Good Clinical Laboratory Practice), and ISO/IEC 17025 principles. Data integrity is ensured in line with ALCOA+ principles, supported by audit trail mechanisms for retrospective traceability.

Key quality system elements include:

  • SOP management and revision control; personnel competency records
  • Method validation/verification (study-fit): specificity, sensitivity, reproducibility, measurement range; LoD/LoQ where applicable
  • Deviation management and CAPA (Corrective and Preventive Action) processes
  • Data security and access control; archiving and audit-ready documentation
Home Sampling for Clinical Research

In protocol-permitted scenarios, virological samples may be collected in the home setting by trained healthcare personnel. The primary objective in this model is ensuring that the right sample is collected at the right time, under the right conditions, and transported appropriately to the laboratory.

Laboratory, analytical, and operational services provided within the Omega ecosystem are delivered through Omega’s internal units or authorized partner infrastructures that comply with applicable standards, depending on the nature of the study, regulatory requirements, and methodological scope.

Accreditations, certifications, and official authorizations apply at the level of the unit or partner organization where the service is actually performed and are assessed on a study-specific basis for each service category.